Skip to main content

Study

High-Dose CBD Does Not Improve Knee Osteoarthritis Pain in Seniors

Adding high-dose CBD to paracetamol showed no additional pain relief for knee osteoarthritis sufferers.

Joint HealthPain ManagementHealthy AgingSupplements
Study Credibility: High8.8/10From a trusted journalProperly designed studyResults verified
PublishedSep 2026Last reviewedSep 2026
Email this

Summary

In plain language

Researchers investigated whether taking high-dose cannabidiol (CBD) along with paracetamol could help reduce knee pain from osteoarthritis. The study involved 86 participants, most of whom were seniors, who took either CBD or a placebo for 8 weeks. Results showed that both groups experienced similar levels of pain relief, indicating that CBD did not provide additional benefits. Moreover, those taking CBD reported more side effects, particularly related to liver enzymes. This study suggests that CBD may not be a helpful supplement for managing osteoarthritis pain in the knee. Seniors considering CBD should discuss its benefits and risks with their healthcare providers.

Details

Use the full description to understand the study design, methods, and the limits of the findings.

This study aimed to explore if adding high-dose CBD to regular paracetamol treatment could ease knee osteoarthritis pain more effectively than a placebo. It was a randomized, double-blind trial involving 86 adults, mainly seniors, with chronic knee pain. Participants took either 600 mg of CBD or a placebo daily for 8 weeks.

  • Both groups showed similar pain reduction, with no significant difference between those taking CBD and those taking a placebo.

  • Participants using CBD experienced more side effects, particularly concerning liver enzyme levels.

  • The study concluded that high-dose CBD does not enhance pain relief when added to paracetamol for knee osteoarthritis.

Seniors should consult with their healthcare providers before adding CBD to their treatment plans, considering the lack of additional benefits and potential side effects.

Research Quality Score

Scored September 27, 2026 using rubric mq-1.8_2026-07-06.

Assessment

The study scored highly due to its rigorous design, including randomization, blinding, and allocation concealment. It was well-powered with pre-specified endpoints and transparent reporting. The absence of conflicts of interest and publication in a high-tier journal further supported its quality. However, the lack of replication evidence slightly reduced the overall score.

Category Breakdown

CategoryScoreRating
Study design10.0/10
Bias control10.0/10
Statistical methods10.0/10
Reporting completeness10.0/10
Conflicts & funding10.0/10
Replication0.0/10
Relevance to chosen population10.0/10
Journal Reliability5.0/10

Additional Notes

This randomized, double-blind, placebo-controlled trial evaluated the effect of high-dose oral CBD as an add-on to paracetamol in seniors with knee osteoarthritis. It found no significant analgesic benefit of CBD over placebo after 8 weeks.

Assessed on the study's full text across 8 quality dimensions; conflict-of-interest disclosures were reviewed.

Take the next step

Build a personalized plan using research-backed studies, conditions, and treatments.